THE BAD NEWS? ALL THREE of the COVID-19 vaccines approved in the United States seem to be significantly less protective against the new Omicron variant...

What’s the one best thing I can do for my health? This question tends to come up around the new year. In my clinical...

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.